Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESIST-2: HIV-2 Viral Load and Resistance Informed 2nd-line ART
NCT03394196Terminated
- Sponsor
- University of Washington
- Start
- Jul 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of raltegravir and darunavir in human immunodeficiency virus type 2 infection (HIV-2) (3 arms), sponsored by University of Washington. Primary endpoints: Death up to 3 years, Loss to follow up at 1 year and 2 more. Started Jul 2018; status: terminated.
02
Drugs
raltegravirdarunavir
03
Conditions
human immunodeficiency virus type 2 infection (HIV-2)
Beyond the preview
Go deeper on NCT03394196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03394196.